Exhibit 99.1 Viking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • VK2735 to Advance to Phase 3 for Obesity; End-of-Phase 2 Meeting Planned for 2H24 • Oral VK2735 Phase 2 Study in Obesity Expected to Begin 4Q24 • Positive Biopsy Results From VK2809 Reported in June; End-of-Phase 2 Meeting in NASH/MASH Planned for 4Q24 • Enrollment Completed in Phase 1b Study of VK0214 for X-ALD; Data Expected 2H24 • In Vivo Data Fro ...

VK2735 to Advance to Phase 3 for Obesity; End-of-Phase 2 Meeting Planned for 2H24 Enrollment Completed in Phase 1b Study of VK0214 for X-ALD; Data Expected 2H24 "The first half of 2024 was marked by strong momentum in the company's pipeline programs, as we reported successful outcomes from three different clinical trials, and began preparing for next steps with each program," stated Brian Lian, Ph.D., chief executive officer of Viking. "The Phase 2 VENTURE study of VK2735 in obesity demonstrated up to an ap ...

wragg For this particular article, we will be looking at Viking Therapeutics, Inc. (NASDAQ:NASDAQ:VKTX) and sharing our findings about the stock, continuing the theme surrounding obesity therapies. VKTX For now, VK2735 has already reported excellent results from its phase 2 clinical trials, with 14.7% of weight loss from base line by Week 13 (subcutaneous injection) and 5.3% by Day 28 (oral). These numbers are very promising indeed, since it delivers excellent weight losses compared to NVO's Wegovy at -7% a ...

Viking's loss estimates have increased from $1.08 per share to $1.11 for 2024 and from $1.42 to $1.45 for 2025 in the past 60 days. Zacks Investment Research Surprise - Reported Earnings History 0 Earnings Whispers Without an approved/marketed product in its portfolio, the focus is expected to be on updates related to Viking's pipeline consisting of three candidates — VK2735 (for obesity), VK2809 (for non-alcoholic steatohepatitis [NASH]) and VK0214 (for X-linked adrenoleukodystrophy (X-ALD)]. Viking Therap ...

This biotech stock fits the profile of a potentially big winner to a T. Fortunes have been made on biotech stocks over the last few decades. The secret to success has been to invest in an up-and-coming biotech company before it even had a product on the market. Ideally, the company would have a pipeline featuring multiple promising candidates with significant commercial potential. Viking Therapeutics (VKTX 0.52%) fits the profile of such a stock to a T. Could Viking be a millionairemaker? What's in Viking T ...

The company's stock has dropped by 1.58% in the past month, falling short of the Medical sector's gain of 2.23% and the S&P 500's gain of 2.14%. Any recent changes to analyst estimates for Viking Therapeutics, Inc. should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 ...

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2809, a novel, orally available, small molecule selective thyroi ...

Let's look beyond the hype the company is generating this year. Could 2024 be a breakout year for Viking Therapeutics (VKTX -4.01%)? The mid-cap biotech has generated more positive headlines than most of its peers. Excitement is through the roof. Due to crucial clinical progress, Viking Therapeutics' shares have tripled this year. Biotech investors have noticed, but many remain on the sidelines wondering whether Viking is the right choice for them -- or whether the stock is a one-hit (or one-year) wonder. L ...

Viking's stock has tripled in less than a year, and its red-hot valuation could have investors thinking twice about buying it today. It's not only Viking's share price that has been falling; volume is down, too Investors could still be waiting a long time for approval of a treatment Meanwhile, many top healthcare companies are developing weight loss drugs of their own to try to grab a piece of the lucrative anti-obesity market, which could grow to be worth $100 billion by 2030, according to estimates from G ...

Sasha Brazhnik/iStock via Getty Images +3.02 (5.93%) 100.00 90.00 80.00 70.00 60.00 40.00 54.03 50.00 30.00 10.00 Jul The weight loss drug sector is seeing an incecasingly intensified drug development focus, causing a small player like Viking Therapeuties, Inc. (NASDAQ:VKTX) to The wegen world, broken in metelings meaning due, est lest, but the fear is not one mail pay than your man partier for O.P-1 man arte norse. slip. The small biotech has has Potentially Crowded Market VIKING Goldman Sachs has jumped M ...